AccuStem Sciences Reports Q3 2025 Financial Results with Increased Losses and Strategic Developments

AccuStem Sciences Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $399,897, compared to a loss of $328,174 in the same period of 2024. For the nine months ending September 30, 2025, the company recorded a net loss of $1,241,708, an increase from the $1,133,001 loss reported for the same period in the previous year. The company's total operating expenses for the third quarter were $399,897, up 22% from $328,174 in the prior year, primarily driven by increased research and development costs, which rose by 132% to $72,720, and general and administrative expenses, which increased by 10% to $327,177.

AccuStem's financial position has seen significant changes since the end of 2024. As of September 30, 2025, the company reported total assets of $1,573,247, a substantial increase from $50,851 at the end of 2024. This growth was largely attributed to an advance payment of $1.5 million, which is expected to facilitate the acquisition of an intangible asset. However, total liabilities also increased to $4,484,157 from $3,364,075, primarily due to higher accounts payable and related party payables. The company's accumulated deficit has now reached $9,268,755, reflecting ongoing operational losses.

In terms of strategic developments, AccuStem is focused on advancing its product pipeline, particularly the MicroRNA Signature Classifier (MSC) and StemPrintER tests. The MSC test, aimed at assessing lung nodules, is expected to launch for clinical use in early 2026. The company has partnered with EmeritusDx to facilitate the testing process and is working towards obtaining necessary certifications. The StemPrintER test, designed for early-stage breast cancer patients, is also in the pipeline for commercialization. These products are positioned to tap into a significant market opportunity, estimated at over $6.3 billion annually in the U.S.

Operationally, AccuStem has not yet generated revenue and continues to rely on funding from related parties to support its activities. The company reported a cash balance of $14,391 as of September 30, 2025, a decrease from $37,080 at the same time last year. The company anticipates that it will require additional financing to support its ongoing research and development efforts and to cover operational costs. Management is actively pursuing equity financing options and has engaged in discussions with institutional investors to secure necessary funds.

Looking ahead, AccuStem expects to continue incurring losses as it invests in the development and commercialization of its product candidates. The company acknowledges the need for significant additional cash resources to sustain its operations and achieve its strategic goals. Management has indicated that the ability to secure funding will be critical to the company's future, as it aims to navigate the complexities of product development and market entry in the competitive oncology diagnostics landscape.